SCHEMBL4548465

SCHEMBL4548465

COC(=O)C1=C(N)C[C@@H](C)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.39
MAPT P10636 7/20 0.39
HPGD P15428 5/20 0.39
KDM4E B2RXH2 5/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
HSD17B10 Q99714 6/20 0.38
ALOX15 P16050 3/20 0.38
ALOX12 P18054 2/20 0.38
GAA P10253 2/20 0.38
TSHR P16473 1/20 0.38
POLB P06746 2/20 0.38
MAPK1 P28482 2/20 0.38
DUSP3 P51452 1/20 0.38
PTPN5 P54829 1/20 0.38
PTPN11 Q06124 1/20 0.38
TLR2 O60603 1/20 0.35
TP53 P04637 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4548482 1.00 ALDH1A1 (0.39) ALDH1A1MAPTHPGDKDM4ENPC1
SCHEMBL24373045 0.81 ALDH1A1 (0.55) ALDH1A1MAPTHPGDKDM4ENPC1
SCHEMBL2646503 0.80 MEN1 (0.38) ALDH1A1MAPTHPGDKDM4ENPC1
SCHEMBL4548479 0.76 NOS3 (0.35) ALDH1A1MAPTHPGDKDM4ENPC1
SCHEMBL4548485 0.76 PTGER4 (0.33) ALDH1A1MAPTHPGDKDM4ENPC1
SCHEMBL7950766 0.75 KDM4E (0.46) ALDH1A1MAPTHPGDKDM4ENPC1
SCHEMBL1144125 0.72 SLC6A3 (0.46) ALDH1A1HPGDKDM4EHSD17B10GAA
SCHEMBL1400009 0.72 SLC6A3 (0.46)
SCHEMBL24358918 0.71 NOS3 (0.33) ALDH1A1MAPTHPGDKDM4EHSD17B10
SCHEMBL24359051 0.71 NOS3 (0.33) ALDH1A1MAPTHPGDKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178750-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME CORP. (US) 2012-07-12 US disclosed
US-20120178750-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME CORP. (US) 2012-07-12 US disclosed
US-8168649-B2 Niacin receptor agonists, compositions containing such compounds and methods of treatment Merk Sharp & Dohme Corp. (US) 2012-05-01 US disclosed
US-8168649-B2 Niacin receptor agonists, compositions containing such compounds and methods of treatment Merk Sharp & Dohme Corp. (US) 2012-05-01 US disclosed
US-20100144778-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME LLC 2010-06-10 US disclosed
US-20100144778-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME LLC 2010-06-10 US disclosed
WO-2007002557-A1 NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK & CO., INC. (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144778-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment HCAR1, HCAR2, GPR119 ALDH1A1 1145/4885MAPT 2721/4885HPGD 149/4885
US-20120178750-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment HCAR1, HCAR2, FFAR1 ALDH1A1 1106/4885MAPT 2701/4885HPGD 159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.